Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension

References

• Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
   Google Scholar
• Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–735. doi:10.1053/j.ajkd.2014.01.416.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S, et al. Resistant. Hypertension. 2008;51(6):1403–1419. doi:10.1161/HYPERTENSIONAHA.108.189141.
   PubMed Web of Science ®Google Scholar
• Kumbhani DJ, Steg PG, Cannon CP, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34(16):1204–1214. doi:10.1093/eurheartj/ehs368.
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–1642. doi:10.1161/CIRCULATIONAHA.111.068064.
   PubMed Web of Science ®Google Scholar
• Thomas G, Xie D, Chen HY, et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study. Hypertension. 2016;67(2):387–396. doi:10.1161/HYPERTENSIONAHA.115.06487.
   PubMed Web of Science ®Google Scholar
• Coresh J, Heerspink HJL, Sang Y, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7(2):115–127. doi:10.1016/S2213-8587(18)30313-9.
   PubMed Web of Science ®Google Scholar
• Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84–104. doi:10.1053/j.ajkd.2019.06.009.
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, Kröpelin TF, Hoekman J, et al. Drug-induced reduction in albuminuria Is associated with subsequent renoprotection. J Am Soc Nephrol. 2015;26(8):2055–2064. doi:10.1681/ASN.2014070688.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743–754. doi:10.1016/S2213-8587(21)00242-4.
   PubMed Web of Science ®Google Scholar
• Kaboré J, Metzger M, Helmer C, et al. Kidney function decline and apparent treatment-resistant hypertension in the elderly. PLoS One. 2016;11(1):e0146056. doi:10.1371/journal.pone.0146056.
   PubMed Web of Science ®Google Scholar
• Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68:297–306. doi:10.1161/HYPERTENSIONAHA.116.07464.
   Google Scholar
• Jelínek L, Václavík J, Ramík Z, et al. Directly measured adherence to treatment in chronic heart failure: LEVEL-CHF registry. Am J Med Sci. 2021;361(4):491–498. doi:10.1016/j.amjms.2020.12.004.
   PubMed Web of Science ®Google Scholar
• Fay KS, Cohen DL. Resistant hypertension in people with CKD: a review. Am J Kidney Dis. 2021;77(1):110–121. doi:10.1053/j.ajkd.2020.04.017.
   PubMed Web of Science ®Google Scholar
• Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C–based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–1749. doi:10.1056/NEJMoa2102953.
   PubMed Web of Science ®Google Scholar
• Parati G, Stergiou GS, Asmar R, et al. European society of hypertension guidelines for blood pressure monitoring at home: a summary report of the second international consensus conference on home blood pressure monitoring. J Hypertens. 2008;26(8):1505–1526. doi:10.1097/HJH.0b013e328308da66.
   PubMed Web of Science ®Google Scholar
• Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009;120:419–428, PMID: 19768194 PMCID: PMC2744545.
   PubMedGoogle Scholar
• Davies DF, Shock NW. Age changes IN glomerular filtration rate, effective renal plasma flow, AND tubular excretory capacity IN adult males. J Clin Invest. 1950;29(5):496–507. doi:10.1172/JCI102286.
   PubMed Web of Science ®Google Scholar
• Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278–285. doi:10.1111/j.1532-5415.1985.tb07117.x.
   PubMed Web of Science ®Google Scholar
• Mc Causland FR, Claggett BL, Vaduganathan M, et al. Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 2023;9(2):144–152. doi:10.1001/jamacardio.2023.4664.
   Web of Science ®Google Scholar
• Sharma A, Ferreira JP, Zannad F, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial. Eur J Heart Fail. 2023;25(8):1337–1348. doi:10.1002/ejhf.2857.
   PubMedGoogle Scholar
• Cherney DZI, Cosentino F, Dagogo-Jack S, et al. Ertugliflozin and slope of chronic eGFR. Clin J Am Soc Nephrol. 2021;16(9):1345–1354. doi:10.2215/CJN.01130121.
   PubMed Web of Science ®Google Scholar
• Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237–1250. doi:10.1111/dom.13648.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Vart P, Jongs N, et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021;32(9):2352–2361. doi:10.1681/ASN.2021020167.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi:10.1056/NEJMoa2024816.
   PubMed Web of Science ®Google Scholar
• Jardine MJ, Zhou Z, Mahaffey KW, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020;31(5):1128–1139. doi:10.1681/ASN.2019111168.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744.
   PubMed Web of Science ®Google Scholar
• Cao H, Rao X, Jia J, et al. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2023;60(3):325–335. doi:10.1007/s00592-022-01989-7.
   PubMed Web of Science ®Google Scholar
• Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-Like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022;145(8):575–585. doi:10.1161/CIRCULATIONAHA.121.055459.
   PubMed Web of Science ®Google Scholar
• Holtkamp FA, De Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282–287. doi:10.1038/ki.2011.79.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Ferreira JP, Rossignol P, et al. Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. Eur J Heart Fail. 2022;24(9):586–1590. doi:10.1002/ejhf.2635.
   Web of Science ®Google Scholar
• Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022;24(9):1591–1598. doi:10.1002/ejhf.2421.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Coresh J, Ballew SH, et al. Past decline versus current EGFR and subsequent ESRD risk. J Am Soc Nephrol. 2016;27(8):2447–2455. doi:10.1681/ASN.2015060687.
   PubMed Web of Science ®Google Scholar
• Grams ME, Sang Y, Ballew SH, et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. J Am Soc Nephrol. 2019;30(9):1746–1755. doi:10.1681/ASN.2019010008.
   PubMed Web of Science ®Google Scholar
• Denker M, Boyle S, Anderson AH, et al. Chronic renal insufficiency cohort study (CRIC). Clin J Am Soc Nephrol. 2015;10(11):2073–2083. doi:10.2215/CJN.04260415.
   PubMed Web of Science ®Google Scholar
• Lash JP, Go AS, Appel LJ, et al. Chronic renal insufficiency cohort (CRIC) study: baseline characteristics and associations with kidney function. Clin JAm Soc Nephrol. 2009;4(8):1302–1311. Available from: https://journals.lww.com/cjasn/Fulltext/2009/08000/Chronic_Renal_Insufficiency_Cohort__CRIC__Study_.4.aspx doi:10.2215/CJN.00070109.
   PubMed Web of Science ®Google Scholar
• Tanner RM, Calhoun DA, Bell EK, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8(9):1583–1590. doi:10.2215/CJN.00550113.
   PubMed Web of Science ®Google Scholar
• Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-Stage renal disease. Hypertension. 2014;64(5):1012–1021. doi:10.1161/HYPERTENSIONAHA.114.03850.
   PubMed Web of Science ®Google Scholar
• Viazzi F, Piscitelli P, Ceriello A, et al. Resistant hypertension, time‐updated blood pressure values and renal outcome in type 2 diabetes mellitus. J Am Heart Assoc. 2017;6(0 ):e006745. doi:10.1161/JAHA.117.006745.
   PubMedGoogle Scholar
• Pignatelli P, Farcomeni A, Menichelli D, et al. Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. Intern Emerg Med. 2020;15(1):135–143. doi:10.1007/s11739-019-02204-2.
   PubMed Web of Science ®Google Scholar
• Ronit A, Kirkegaard-Klitbo DM, Dohlmann TL, et al. Plasma albumin and incident cardiovascular disease. Arterioscler Thromb Vasc Biol. 2020;40(2):473–482. doi:10.1161/ATVBAHA.119.313681.
   PubMed Web of Science ®Google Scholar
• Desai R, Park H, Brown JD, et al. Comparative safety and effectiveness of aldosterone antagonists Versus beta-Blockers as fourth agents in patients With apparent resistant hypertension. Hypertension. 2022;79(10):2305–2315. doi:10.1161/HYPERTENSIONAHA.122.19280.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. doi:10.1056/NEJMoa2025845.
   PubMed Web of Science ®Google Scholar
• Ramik Z, Vaclavik J, Kocianova E, et al. Long-term decline of renal function in patients with resistant and non-resistant arterial hypertension. Eur Heart J. 2022;43(2):ehac544.2226. doi:10.1093/eurheartj/ehac544.2226.
   Google Scholar
• Ramik Z, Vaclavik J, Kvapil T, et al. Renal function IN comparison TO non-resistant arterial hypertension. J Hypertens. 2022;40(1):e287. doi:10.1097/01.hjh.0000838504.91361.bc.
   Google Scholar